Results 151 to 160 of about 237,304 (188)
Some of the next articles are maybe not open access.

ISIS

ACM Transactions on Computer-Human Interaction, 2004
ISIS (Intelligent Speech for Information Systems) is a trilingual spoken dialog system (SDS) for the stocks domain. It handles two dialects of Chinese (Cantonese and Putonghua) as well as English---the predominant languages in our region. The system supports spoken language queries regarding stock market information and simulated personal portfolios ...
Helen Meng   +4 more
openaire   +1 more source

Isis

Proceedings of the 20th ACM SIGKDD international conference on Knowledge discovery and data mining, 2014
We describe ISIS, a high-performance-computing-based application to support computational epidemiology of infectious diseases. ISIS has been developed over the last seven years in close coordination with public health and policy experts. It has been used in a number of important federal planning and response exercises.
Richard Beckman   +5 more
openaire   +2 more sources

ISIS-3521. Isis Pharmaceuticals.

Current opinion in investigational drugs (London, England : 2000), 2002
ISIS-3521 is a 20-mer antisense phosphorothioate oligonucleotide PKCa expression inhibitor, under development by Isis (formerly in collaboration with Novartis) for the potential treatment of solid tumors that are refractory to, or recurrent with, standard treatment regimens [175741].
K, Li, J, Zhang
openaire   +1 more source

ISIS

Proceedings of the 1985 ACM SIGMOD international conference on Management of data, 1985
ISIS IS an experimental system for graphically manlpulatmg a database The system 1s based on a simply specified high-level semantic data model It demonstrates the capablbtles of a workstation environment by mtegratmg three aspects of database programming m one graphical setting Namely, it permits database constructlon and modification, it allows ...
Kenneth J. Goldman   +3 more
openaire   +1 more source

ISIS-14803 (Isis Pharmaceuticals).

Current opinion in investigational drugs (London, England : 2000), 2002
Isis and Merck are developing an antisense oligonucleotide for the potential treatment of hepatitis C virus (HCV) infection [305306]. As of March 2000, the lead from this program, ISI-14803, was being studied in a phase I/II trial where it was administered in three weekly 2-h infusions for 4 weeks [327913], [357823].
openaire   +1 more source

Technology evaluation: ISIS-113715, Isis.

Current opinion in molecular therapeutics, 2005
Isis is developing ISIS-113715, an antisense inhibitor of the PTP1B gene, for the potential treatment of type 2 diabetes and obesity. ISIS-113715 is undergoing phase II clinical trials.
openaire   +1 more source

What Explains the Flow of Foreign Fighters to ISIS?

Terrorism and Political Violence, 2020
Efraim Benmelech, Esteban F Klor
exaly  

Home - About - Disclaimer - Privacy